Gina Tomaine

News

Bendamustine Demonstrates Safety, Efficacy for Lymphodepletion Before Tisagenlecleucel in R/R Large B-Cell Lymphoma

09/30/2022

Bendamustine is an effective lymphodepletion regimen before tisagenlecleucel in patients with refractory/relapsed large B-cell lymphomas, according to a recent study.

Bendamustine is an effective...

09/30/2022

Oncology

News

Bevacizumab Biosimilar Candidate TAB008 Comparable to Reference Bevacizumab for Patients With Locally Advanced, Metastatic EGFR Wild-Type Non-Squamous NSCLC

07/10/2023

Gina Tomaine ;

In a phase 3 study, biosimilar candidate TAB008 was found to be similar to reference bevacizumab in terms of efficacy and safety for patients with locally advanced, metastatic EGFR wild-type non-squamous non-small cell lung cancer.

In a phase 3 study, biosimilar...

07/10/2023

Oncology

News

Mosunetuzumab Demonstrates Safety, Efficacy in Patients With Relapsed/Refractory Follicular Lymphoma

11/17/2022

Gina Tomaine ;

CD20-CD3 bispecific antibody mosunetuzumab demonstrated a favorable safety profile and induced high rates of complete remission in patients with relapsed/refractory follicular lymphoma, according to a phase 2 study.

CD20-CD3 bispecific antibody...

11/17/2022

Oncology

Natalizumab Plus Corticosteroid Regimen Ineffective in Improving Outcomes for Newly Diagnosed High-Risk GI GVHD

09/28/2023

Gina Tomaine ;

A regimen of natalizumab combined with corticosteroids was generally well-tolerated but did not improve outcomes for patients with newly diagnosed high-risk GI GVHD, according to a phase 2 study.

A regimen of natalizumab...

09/28/2023

Oncology

News

Treatment Regimen Using Non–Anthracycline-Containing Backbone is Effective for Older Patients With AML

08/19/2022

Gina Tomaine ;

Venetoclax added to cladribine and low-dose cytarabine alternating with venetoclax and 5-azacitidine demonstrated efficacy among older or unfit patients with newly diagnosed AML, according to results from a phase 2 trial.

Venetoclax added to cladribine...

08/19/2022

Oncology

News

FDA Approves Teclistamab for Patients With Relapsed/Refractory MM

10/27/2022

Gina Tomaine ;

The FDA granted accelerated approval to teclistamab for the treatment of adult patients with relapsed or refractory MM who received ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38...

The FDA granted accelerated...

10/27/2022

Oncology

News

Obinutuzumab, Acalabrutinib, and Venetoclax Combination After Optional Debulking With Bendamustine Not Recommended in R/R CLL

09/30/2022

Gina Tomaine ;

Triple therapy with obinutuzumab, acalabrutinib, and venetoclax after an optional debulking with bendamustine regimen is not currently recommended for R/R CLL, according to a phase 2 study.

Triple therapy with...

09/30/2022

Oncology

News

Bendamustine–Ofatumumab Combination Effective as Frontline Therapy for Older Patients With MCL

09/14/2022

Gina Tomaine ;

Ofatumumab plus bendamustine is an effective and well-tolerated combination therapy for the first-line treatment of older patients with mantle cell lymphoma, according to a phase 2 study.

Ofatumumab plus bendamustine is...

09/14/2022

Oncology

News

Zanubrutinib Demonstrates Favorable Long-term Efficacy and Safety in Relapsed/Refractory MCL

07/13/2022

Gina Tomaine ;

Findings from a phase 2 trial show zanubrutinib demonstrates deep and durable responses and a favorable safety profile in relapsed/refractory MCL at a median follow-up of 35.3 months.

Findings from a phase 2 trial...

07/13/2022

Oncology

News

FDA Approves Olutasidenib for Patients With Relapsed/Refractory IDH1-Mutant AML

12/06/2022

Gina Tomaine ;

The FDA granted approval to olutasidenib for adult patients with relapsed/refractory AML and a susceptible IDH1 mutation, as detected by an FDA-approved test.

The FDA granted approval to...

12/06/2022

Oncology